Ting Chang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ting Chang has a total of 290 co-authors. Here are the top co-authors by number of shared publications:
Zhe Ruan
Department of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi’an, China
21 shared publicationsRongjing Guo
Department of Neurology, Tangdu Hospital, The Fourth Military Medical University
17 shared publicationsTing Gao
Department of Neurology, Tangdu Hospital, The Fourth Military Medical University
16 shared publicationsChao Sun
Department of Neurology, Tangdu Hospital, The Fourth Military Medical University
15 shared publicationsYonglan Tang
Department of Neurology, Tangdu Hospital, The Fourth Military Medical University
15 shared publicationsYue Su
Department of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi’an, China
14 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by Wiley in JIMD Reports
- Vol. 67 (6)
High‐Risk Screening for Late‐Onset Pompe Disease in Northern China: Prevalence, Genotypic Spectrum, and Diagnostic Challenges
Late‐onset Pompe disease (LOPD), also known as late‐onset glycogen storage disease Type II, is caused by a genetic deficiency of the lysosomal enzyme acid α‐glucosidase (GAA). LOPD typically results in progressive weakness of the limb‐girdle and respiratory muscles and is often accompanied by the involvement of other systems, such as skeleton, smooth muscle, and the cerebrovascular system. The incidence of LOPD in China remains unknown, underscoring the need for large‐scale epidemiological studies to better characterize the clinical spectrum. This prospective, multicenter, observational cohort study was conducted across 39 neurology centers in 12 northern Chinese provinces. A novel pragmatic approach was utilized, which included the development and application of a standardized high‐risk profile for LOPD suspicion, derived from collective diagnostic and therapeutic experience throughout the region. Individuals meeting 2 or more criteria in this predefined high‐risk profile were enrolled. Subsequent screening involved initial analysis of GAA enzyme activity using dried blood spot (DBS) testing and patients with deficient enzyme activity underwent confirmatory genetic testing to establish a definitive LOPD diagnosis. Between January 2022 and December 2024, 1878 high‐risk patients were enrolled. Screening identified 46 patients (2.45%) diagnosed with LOPD based on DBS analysis and subsequent genetic confirmation. This study demonstrates a significant prevalence of LOPD among a clinically high‐risk population in Northern China. These findings underscore the critical importance of targeted screening programs for early identification. Early diagnosis enables timely initiation of enzyme replacement therapy (ERT), which can significantly mitigate the disease course, improve quality of life, and reduce long‐term healthcare burden.
- 13 November 2026
- Published by Wiley in JIMD Reports
- Vol. 67 (6)
Open AccessHigh‐Risk Screening for Late‐Onset Pompe Disease in Northern China: Prevalence, Genotypic Spectrum, and Diagnostic Challenges
Late‐onset Pompe disease (LOPD), also known as late‐onset glycogen storage disease Type II, is caused by a genetic deficiency of the lysosomal enzyme acid α‐glucosidase (GAA). LOPD typically results in progressive weakness of the limb‐girdle and respiratory muscles and is often accompanied by the involvement of other systems, such as skeleton, smooth muscle, and the cerebrovascular system. The incidence of LOPD in China remains unknown, underscoring the need for large‐scale epidemiological studies to better characterize the clinical spectrum. This prospective, multicenter, observational cohort study was conducted across 39 neurology centers in 12 northern Chinese provinces. A novel pragmatic approach was utilized, which included the development and application of a standardized high‐risk profile for LOPD suspicion, derived from collective diagnostic and therapeutic experience throughout the region. Individuals meeting 2 or more criteria in this predefined high‐risk profile were enrolled. Subsequent screening involved initial analysis of GAA enzyme activity using dried blood spot (DBS) testing and patients with deficient enzyme activity underwent confirmatory genetic testing to establish a definitive LOPD diagnosis. Between January 2022 and December 2024, 1878 high‐risk patients were enrolled. Screening identified 46 patients (2.45%) diagnosed with LOPD based on DBS analysis and subsequent genetic confirmation. This study demonstrates a significant prevalence of LOPD among a clinically high‐risk population in Northern China. These findings underscore the critical importance of targeted screening programs for early identification. Early diagnosis enables timely initiation of enzyme replacement therapy (ERT), which can significantly mitigate the disease course, improve quality of life, and reduce long‐term healthcare burden.
- 12 October 2026
- Published by Wiley in Muscle & Nerve
- Vol. 74 (6) , 1627-1635
The Efficacy and Safety of Tocilizumab in the Treatment of Refractory Ocular Myasthenia Gravis in Pediatric Patients
Introduction/Aims: Refractory pediatric ocular myasthenia gravis (OMG) remains difficult to manage. We evaluated tocilizumab's efficacy and safety in these patients. Methods: In this single‐center, retrospective analysis of prospectively collected registry data from Tangdu Hospital (China), pediatric refractory OMG patients received intravenous tocilizumab (8 mg/kg every 4 weeks) for 16 weeks as add‐on therapy. Refractory disease required persistent symptoms despite adequate trials of ≥ 2 immunosuppressants, frequent relapses during glucocorticoid tapering, or intolerance of conventional oral immunosuppressants. The primary outcome was change in Myasthenia Gravis‐Activities of Daily Living (MG‐ADL) score from baseline to Weeks 4, 8, 12, and 16, analyzed using generalized estimating equations. Results: All 10 patients (1 male, 9 females; median age 5.5 years, range 2–11) completed 16 weeks of follow‐up. Seven (70%) were positive for antiacetylcholine receptor antibody (AChR‐Ab). At Week 4, mean MG‐ADL score decreased from 3.4 to 2.5 (incidence rate ratio[IRR], 0.74; 95% CI, 0.54–0.99; p = 0.048), with further reduction to 1.5 at week 16 (IRR, 0.44; 95% CI, 0.24–0.80; p = 0.007). Similarly, mean Quantitative MG (QMG) score dropped from 4.7 at baseline to 3.0 at Week 4 (IRR, 0.64; 95% CI, 0.41–0.99; p = 0.048) and further to 1.9 at Week 16 (IRR, 0.40; 95% CI, 0.24–0.69; p = 0.001). By Week 16, 50% of patients achieved minimal symptom expression, and 50% reduced prednisone requirements. Tocilizumab was well‐tolerated with only one transient infusion‐related dizziness. Discussion: These preliminary findings suggest that tocilizumab may offer a safe and effective treatment option for children with refractory OMG.
- 12 October 2026
- Published by Wiley in Muscle & Nerve
- Vol. 74 (6) , 1627-1635
The Efficacy and Safety of Tocilizumab in the Treatment of Refractory Ocular Myasthenia Gravis in Pediatric Patients
Introduction/Aims: Refractory pediatric ocular myasthenia gravis (OMG) remains difficult to manage. We evaluated tocilizumab's efficacy and safety in these patients. Methods: In this single‐center, retrospective analysis of prospectively collected registry data from Tangdu Hospital (China), pediatric refractory OMG patients received intravenous tocilizumab (8 mg/kg every 4 weeks) for 16 weeks as add‐on therapy. Refractory disease required persistent symptoms despite adequate trials of ≥ 2 immunosuppressants, frequent relapses during glucocorticoid tapering, or intolerance of conventional oral immunosuppressants. The primary outcome was change in Myasthenia Gravis‐Activities of Daily Living (MG‐ADL) score from baseline to Weeks 4, 8, 12, and 16, analyzed using generalized estimating equations. Results: All 10 patients (1 male, 9 females; median age 5.5 years, range 2–11) completed 16 weeks of follow‐up. Seven (70%) were positive for antiacetylcholine receptor antibody (AChR‐Ab). At Week 4, mean MG‐ADL score decreased from 3.4 to 2.5 (incidence rate ratio[IRR], 0.74; 95% CI, 0.54–0.99; p = 0.048), with further reduction to 1.5 at week 16 (IRR, 0.44; 95% CI, 0.24–0.80; p = 0.007). Similarly, mean Quantitative MG (QMG) score dropped from 4.7 at baseline to 3.0 at Week 4 (IRR, 0.64; 95% CI, 0.41–0.99; p = 0.048) and further to 1.9 at Week 16 (IRR, 0.40; 95% CI, 0.24–0.69; p = 0.001). By Week 16, 50% of patients achieved minimal symptom expression, and 50% reduced prednisone requirements. Tocilizumab was well‐tolerated with only one transient infusion‐related dizziness. Discussion: These preliminary findings suggest that tocilizumab may offer a safe and effective treatment option for children with refractory OMG.
- Open Access
- 12 October 2026
- Published by Springer Nature in Journal of Neuroinflammation
Deficiency of IL-10+KLRG1+ ILC2s drives pathogenic B cell responses in myasthenia gravis
- 12 October 2026
- Published by Springer Nature in Journal of Neuroinflammation
Open AccessDeficiency of IL-10+KLRG1+ ILC2s drives pathogenic B cell responses in myasthenia gravis
- Open Access
- 3 September 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1797461
Effectiveness and safety of telitacicept in refractory ocular myasthenia gravis: a retrospective, real-world study
Introduction: Refractory ocular myasthenia gravis (OMG) remains a significant therapeutic challenge with limited evidence-based biologic therapies. This study aimed to evaluate the effectiveness and safety of telitacicept, a recombinant B-lymphocyte stimulator receptor-antibody fusion protein, in refractory OMG. Methods: This retrospective, single-center observational study assessed clinical outcomes, immunological biomarkers, and safety following add-on telitacicept therapy in refractory OMG. Disease severity was evaluated using the Myasthenia Gravis Activities of Daily Living (MG-ADL), Quantitative Myasthenia Gravis (QMG), and Myasthenia Gravis Impairment Index (MGII) scales. Serum immunoglobulins, complement components, and CD19 + B-cell counts were measured, and adverse events were systematically recorded. Results: Twelve patients with refractory OMG were included. Median baseline MG-ADL, QMG, and MGII scores were 5.5 (interquartile range [IQR] 5.0–6.0), 7.0 (IQR 5.3–8.0), and 16.0 (IQR 12.0–18.0), respectively. Statistically significant improvement was observed as early as week 1 (all p < 0.05). By week 12, MG-ADL scores decreased by a median of 3.0 (95% CI: 2.0–4.0; p < 0.001, r = 0.89), with consistent improvements in QMG and MGII scores (all p < 0.01, all r > 0.85). Minimal symptom expression (MSE) was achieved in 7 of 12 patients (58.3%) within the 12-week period. The median daily prednisone dose was reduced from 15.0 mg (IQR 10.0–22.5) to 9.0 mg (IQR 5.0–13.8) by week 12 (median decrease: 7.5 mg, 95% CI: 2.5–13.5; p = 0.031, r = 0.79), with 1 patient discontinuing corticosteroids by week 8. Telitacicept treatment was associated with reductions in serum IgG, IgA, and IgM levels, alongside increased levels of complement components. No serious adverse events, infections, or treatment discontinuations occurred. Conclusion: Telitacicept was associated with rapid, sustained clinical improvement and a favorable safety profile in refractory OMG, which supports its potential role as an add-on therapeutic option.
- 3 September 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1797461
Open AccessEffectiveness and safety of telitacicept in refractory ocular myasthenia gravis: a retrospective, real-world study
Introduction: Refractory ocular myasthenia gravis (OMG) remains a significant therapeutic challenge with limited evidence-based biologic therapies. This study aimed to evaluate the effectiveness and safety of telitacicept, a recombinant B-lymphocyte stimulator receptor-antibody fusion protein, in refractory OMG. Methods: This retrospective, single-center observational study assessed clinical outcomes, immunological biomarkers, and safety following add-on telitacicept therapy in refractory OMG. Disease severity was evaluated using the Myasthenia Gravis Activities of Daily Living (MG-ADL), Quantitative Myasthenia Gravis (QMG), and Myasthenia Gravis Impairment Index (MGII) scales. Serum immunoglobulins, complement components, and CD19 + B-cell counts were measured, and adverse events were systematically recorded. Results: Twelve patients with refractory OMG were included. Median baseline MG-ADL, QMG, and MGII scores were 5.5 (interquartile range [IQR] 5.0–6.0), 7.0 (IQR 5.3–8.0), and 16.0 (IQR 12.0–18.0), respectively. Statistically significant improvement was observed as early as week 1 (all p < 0.05). By week 12, MG-ADL scores decreased by a median of 3.0 (95% CI: 2.0–4.0; p < 0.001, r = 0.89), with consistent improvements in QMG and MGII scores (all p < 0.01, all r > 0.85). Minimal symptom expression (MSE) was achieved in 7 of 12 patients (58.3%) within the 12-week period. The median daily prednisone dose was reduced from 15.0 mg (IQR 10.0–22.5) to 9.0 mg (IQR 5.0–13.8) by week 12 (median decrease: 7.5 mg, 95% CI: 2.5–13.5; p = 0.031, r = 0.79), with 1 patient discontinuing corticosteroids by week 8. Telitacicept treatment was associated with reductions in serum IgG, IgA, and IgM levels, alongside increased levels of complement components. No serious adverse events, infections, or treatment discontinuations occurred. Conclusion: Telitacicept was associated with rapid, sustained clinical improvement and a favorable safety profile in refractory OMG, which supports its potential role as an add-on therapeutic option.
- Open Access
- 28 August 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1907574
Infections and hypogammaglobulinemia in myasthenia gravis patients receiving low-dose rituximab: a real-world cohort study
Aims: We investigated the incidence of infections and hypogammaglobulinemia (HGG) in patients with myasthenia gravis (MG) receiving long-term low-dose rituximab (RTX) maintenance therapy and identified related risk factors. Methods: This single-center retrospective cohort study enrolled MG patients treated with low-dose RTX maintenance. Cox proportional hazards regression was performed to analyze risk factors for infections and HGG. Results: A total of 186 patients were included. The median age at RTX initiation was 52.50 years, and the median follow-up was 2.41 years. Infections occurred in 29 patients (15.59%), with a median time to first infection of 170.37 days, mostly during the first cycle. The 1- and 2-year infection rates were 13.41 (95% confidence interval [CI], 8.47–20.28) and 9.20 (95% CI, 6.06–13.36) per 100 person-years. Severe infections developed in 21 patients (11.29%). The most prevalent infection was lower respiratory tract infection (LRTI), with 19 episodes (61.29%). HGG was present in 51 patients (27.42%). HGG was an independent risk factor for infection (HR = 5.53, P<0.001). Higher baseline prednisone dose (HR = 1.25, P = 0.035) and HGG (HR = 7.50, P<0.001) were significantly correlated with increased risk of severe LRTIs. Conclusion: In MG patients receiving long-term low-dose RTX maintenance, the overall infection incidence is relatively low, with LRTIs being the most frequent. HGG is a major independent risk factor for infections and severe LRTIs, while higher baseline prednisone doses were associated with severe LRTIs.
- 28 August 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1907574
Open AccessInfections and hypogammaglobulinemia in myasthenia gravis patients receiving low-dose rituximab: a real-world cohort study
Aims: We investigated the incidence of infections and hypogammaglobulinemia (HGG) in patients with myasthenia gravis (MG) receiving long-term low-dose rituximab (RTX) maintenance therapy and identified related risk factors. Methods: This single-center retrospective cohort study enrolled MG patients treated with low-dose RTX maintenance. Cox proportional hazards regression was performed to analyze risk factors for infections and HGG. Results: A total of 186 patients were included. The median age at RTX initiation was 52.50 years, and the median follow-up was 2.41 years. Infections occurred in 29 patients (15.59%), with a median time to first infection of 170.37 days, mostly during the first cycle. The 1- and 2-year infection rates were 13.41 (95% confidence interval [CI], 8.47–20.28) and 9.20 (95% CI, 6.06–13.36) per 100 person-years. Severe infections developed in 21 patients (11.29%). The most prevalent infection was lower respiratory tract infection (LRTI), with 19 episodes (61.29%). HGG was present in 51 patients (27.42%). HGG was an independent risk factor for infection (HR = 5.53, P<0.001). Higher baseline prednisone dose (HR = 1.25, P = 0.035) and HGG (HR = 7.50, P<0.001) were significantly correlated with increased risk of severe LRTIs. Conclusion: In MG patients receiving long-term low-dose RTX maintenance, the overall infection incidence is relatively low, with LRTIs being the most frequent. HGG is a major independent risk factor for infections and severe LRTIs, while higher baseline prednisone doses were associated with severe LRTIs.
- Open Access
- 25 August 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (8) , e71104
Association of Demographic, Clinical, and Environmental Factors With Disease Severity in Adult Myasthenia Gravis: A Multicenter Cross‐Sectional Study
Background: The severity of myasthenia gravis (MG) varies significantly among individuals, yet the factors underlying this heterogeneity are not fully understood. This study aimed to investigate the association between demographic, clinical, and environmental factors and the severity of MG. Methods: From February 2017 to December 2021, adult patients registered in the national MG database were enrolled in this cross‐sectional study. Baseline data on demographic, clinical, and environmental factors (including the natural environment, socioeconomic status, and lifestyle) were collected. Disease severity was classified as mild or moderate to severe using the MG Activities of Daily Living (MG‐ADL) scale and the Quantitative MG (QMG) scale. Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for these associations. Results: A total of 2468 patients were included. The median MG‐ADL score was 3.0 (interquartile range [IQR] 1.0–6.0), and the median QMG score was 6.0 (IQR 3.0–9.0). Higher MG‐ADL scores were associated with age at onset ≥ 65 years (OR 1.85, 95% CI 1.32–2.58), underweight (2.03, 1.35–3.06), generalized onset (2.80, 2.26–3.48), and thymoma (1.70, 1.26–2.30). In contrast, overweight or obesity (OR 0.65, 95% CI 0.52–0.82), medium altitudes (0.64, 0.46–0.90), high educational attainment (0.68, 0.49–0.94), and high monthly household income (0.71, 0.53–0.96) were inversely associated with MG‐ADL scores. Factors associated with higher QMG scores included female sex (OR 1.75, 95% CI 1.28–2.37), age at onset ≥ 65 years (1.91, 1.35–2.71), generalized onset (2.50, 2.00–3.13), thymoma (1.97, 1.43–2.71), medium latitudes (1.53, 1.08–2.16), and high altitudes (1.65, 1.10–2.47). Lower QMG scores were correlated with overweight or obesity (OR 0.78, 95% CI 0.61–0.99), thymectomy (0.57, 0.40–0.81), medium altitudes (0.70, 0.49–0.99), and medium sunlight duration (0.67, 0.49–0.93), as well as higher concentrations of particulate matter with an aerodynamic diameter of ≤ 2.5 μm and higher household income. Conclusion: In addition to demographic and clinical factors, environmental factors may also influence MG severity. Further research is warranted to clarify these associations and their underlying mechanisms.
- 25 August 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (8) , e71104
Open AccessAssociation of Demographic, Clinical, and Environmental Factors With Disease Severity in Adult Myasthenia Gravis: A Multicenter Cross‐Sectional Study
Background: The severity of myasthenia gravis (MG) varies significantly among individuals, yet the factors underlying this heterogeneity are not fully understood. This study aimed to investigate the association between demographic, clinical, and environmental factors and the severity of MG. Methods: From February 2017 to December 2021, adult patients registered in the national MG database were enrolled in this cross‐sectional study. Baseline data on demographic, clinical, and environmental factors (including the natural environment, socioeconomic status, and lifestyle) were collected. Disease severity was classified as mild or moderate to severe using the MG Activities of Daily Living (MG‐ADL) scale and the Quantitative MG (QMG) scale. Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for these associations. Results: A total of 2468 patients were included. The median MG‐ADL score was 3.0 (interquartile range [IQR] 1.0–6.0), and the median QMG score was 6.0 (IQR 3.0–9.0). Higher MG‐ADL scores were associated with age at onset ≥ 65 years (OR 1.85, 95% CI 1.32–2.58), underweight (2.03, 1.35–3.06), generalized onset (2.80, 2.26–3.48), and thymoma (1.70, 1.26–2.30). In contrast, overweight or obesity (OR 0.65, 95% CI 0.52–0.82), medium altitudes (0.64, 0.46–0.90), high educational attainment (0.68, 0.49–0.94), and high monthly household income (0.71, 0.53–0.96) were inversely associated with MG‐ADL scores. Factors associated with higher QMG scores included female sex (OR 1.75, 95% CI 1.28–2.37), age at onset ≥ 65 years (1.91, 1.35–2.71), generalized onset (2.50, 2.00–3.13), thymoma (1.97, 1.43–2.71), medium latitudes (1.53, 1.08–2.16), and high altitudes (1.65, 1.10–2.47). Lower QMG scores were correlated with overweight or obesity (OR 0.78, 95% CI 0.61–0.99), thymectomy (0.57, 0.40–0.81), medium altitudes (0.70, 0.49–0.99), and medium sunlight duration (0.67, 0.49–0.93), as well as higher concentrations of particulate matter with an aerodynamic diameter of ≤ 2.5 μm and higher household income. Conclusion: In addition to demographic and clinical factors, environmental factors may also influence MG severity. Further research is warranted to clarify these associations and their underlying mechanisms.
- Open Access
- 20 June 2026
- Published by Wolters Kluwer Health in Neural Regeneration Research
Chimeric antigen receptor–based cell therapies for neuroimmune disorders: Therapeutic advances and structured standard treatment models
Chimeric antigen receptor-engineered cell therapies provide a novel therapeutic approach for refractory neuroimmune disorders. These cell products penetrate deep into tissue and achieve long-term depletion of pathogenic B cells and plasma cells, supporting sustained immune tolerance and durable clinical remission. Chimeric antigen receptor-T cells, chimeric antigen receptor-natural killer cells, chimeric autoantigen receptor T cells, and chimeric antigen receptor-regulatory T cells selectively target and eliminate pathological immune effectors, reduce autoantibody levels, and help maintain long-term remission in multiple sclerosis, myasthenia gravis, neuromyelitis optica spectrum disorder, chronic inflammatory demyelinating polyneuropathy, and autoimmune encephalitis. This review summarizes the therapeutic advance of chimeric antigen receptor-based cell therapies for neuroimmune disorders. Growing clinical evidence indicates that CD19-directed and B-cell maturation antigen-directed chimeric antigen receptor-T cells provide rapid and persistent clinical improvement even in patients with multiple prior treatment failures, accompanied by depletion of the B-cell lineage and sustained reduction in autoantibody titers. Key mechanisms include enhanced access across the blood-brain barrier, targeted lysis of tissue-resident memory B cells and long-lived plasma cells, and subsequent immune repertoire reconstitution. Important challenges remain incompletely defined, including long-term safety, late relapse, high manufacturing expenses, and restricted availability of autologous cell products. Further advances will require optimized chimeric antigen receptor architectures, off-the-shelf allogeneic platforms, and validation in large controlled clinical trials. This review presents a structured framework for future progress and highlights chimeric antigen receptor based immunotherapy as a pivotal strategy that replaces long term immunosuppression with durable drug free remission, thus reshaping the standard treatment model and redefining therapeutic goals for patients with neuroimmune disorders.
- 20 June 2026
- Published by Wolters Kluwer Health in Neural Regeneration Research
Open AccessChimeric antigen receptor–based cell therapies for neuroimmune disorders: Therapeutic advances and structured standard treatment models
Chimeric antigen receptor-engineered cell therapies provide a novel therapeutic approach for refractory neuroimmune disorders. These cell products penetrate deep into tissue and achieve long-term depletion of pathogenic B cells and plasma cells, supporting sustained immune tolerance and durable clinical remission. Chimeric antigen receptor-T cells, chimeric antigen receptor-natural killer cells, chimeric autoantigen receptor T cells, and chimeric antigen receptor-regulatory T cells selectively target and eliminate pathological immune effectors, reduce autoantibody levels, and help maintain long-term remission in multiple sclerosis, myasthenia gravis, neuromyelitis optica spectrum disorder, chronic inflammatory demyelinating polyneuropathy, and autoimmune encephalitis. This review summarizes the therapeutic advance of chimeric antigen receptor-based cell therapies for neuroimmune disorders. Growing clinical evidence indicates that CD19-directed and B-cell maturation antigen-directed chimeric antigen receptor-T cells provide rapid and persistent clinical improvement even in patients with multiple prior treatment failures, accompanied by depletion of the B-cell lineage and sustained reduction in autoantibody titers. Key mechanisms include enhanced access across the blood-brain barrier, targeted lysis of tissue-resident memory B cells and long-lived plasma cells, and subsequent immune repertoire reconstitution. Important challenges remain incompletely defined, including long-term safety, late relapse, high manufacturing expenses, and restricted availability of autologous cell products. Further advances will require optimized chimeric antigen receptor architectures, off-the-shelf allogeneic platforms, and validation in large controlled clinical trials. This review presents a structured framework for future progress and highlights chimeric antigen receptor based immunotherapy as a pivotal strategy that replaces long term immunosuppression with durable drug free remission, thus reshaping the standard treatment model and redefining therapeutic goals for patients with neuroimmune disorders.
- Open Access
- 10 June 2026
- Published by Springer Nature in Neurology and Therapy
- Vol. 15 (4) , 1973-1992
Eculizumab in Myasthenia Gravis: A Multicenter Retrospective Real-World Study in China
Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder needing long-term immunosuppressive therapy. Eculizumab is a promising treatment, but real-world evidence on its efficacy and safety is limited. This retrospective cohort study across six medical centers enrolled 60 patients with MG on eculizumab. Clinical data, including MG-Activities of Daily Living (MG-ADL) scores, quantitative MG scores (QMG), and oral corticosteroid dosage at baseline, weeks 1, 4, and 8, and final follow-up were obtained. Outcomes included score changes, post-intervention status (PIS), and safety profile. By week 8, 30.95% of patients achieved minimal manifestation status (MMS) or better, increasing to 32.69% at final follow-up. Mean ADL scores significantly dropped from 8.18 ± 3.99 at baseline to 5.59 ± 3.72 at week 1, 3.78 ± 3.42 at week 4, 3.50 ± 2.92 at week 8, and 3.33 ± 3.56 during final follow-up (p < 0.0001). Clinically meaningful improvement (CMI) was observed in 56.9%, 70.0%, 85.0%, and 76.27% at the respective time points. Both thymoma-associated and non-thymoma subgroups showed significant ADL improvement (p ≤ 0.026) with mixed-effects modeling revealing significant group × time interaction (p = 0.01).The thymoma-associated MG (TAMG) group had a faster initial response, with subsequent outcomes comparable between the two groups. Among the 37 patients (61.67%) who switched from FcRn inhibitor therapy to eculizumab, clinical outcomes were non-inferior to those of direct eculizumab recipients and the magnitude of MG-ADL improvement was comparable to that of the overall treatment group. The mean daily corticosteroid dose decreased from 21.21 ± 13.68 mg at baseline to 13.32 ± 10.42 mg at final follow-up (p < 0.0001) Adverse events were rare, with no treatment-related serious events. Eculizumab provides rapid and sustained clinical improvement in patients with MG, with a favorable safety profile. Patients with TAMG show a faster initial response. For patients with an inadequate response to FcRn inhibitors, eculizumab remains an effective rescue strategy.
- 10 June 2026
- Published by Springer Nature in Neurology and Therapy
- Vol. 15 (4) , 1973-1992
Open AccessEculizumab in Myasthenia Gravis: A Multicenter Retrospective Real-World Study in China
Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder needing long-term immunosuppressive therapy. Eculizumab is a promising treatment, but real-world evidence on its efficacy and safety is limited. This retrospective cohort study across six medical centers enrolled 60 patients with MG on eculizumab. Clinical data, including MG-Activities of Daily Living (MG-ADL) scores, quantitative MG scores (QMG), and oral corticosteroid dosage at baseline, weeks 1, 4, and 8, and final follow-up were obtained. Outcomes included score changes, post-intervention status (PIS), and safety profile. By week 8, 30.95% of patients achieved minimal manifestation status (MMS) or better, increasing to 32.69% at final follow-up. Mean ADL scores significantly dropped from 8.18 ± 3.99 at baseline to 5.59 ± 3.72 at week 1, 3.78 ± 3.42 at week 4, 3.50 ± 2.92 at week 8, and 3.33 ± 3.56 during final follow-up (p < 0.0001). Clinically meaningful improvement (CMI) was observed in 56.9%, 70.0%, 85.0%, and 76.27% at the respective time points. Both thymoma-associated and non-thymoma subgroups showed significant ADL improvement (p ≤ 0.026) with mixed-effects modeling revealing significant group × time interaction (p = 0.01).The thymoma-associated MG (TAMG) group had a faster initial response, with subsequent outcomes comparable between the two groups. Among the 37 patients (61.67%) who switched from FcRn inhibitor therapy to eculizumab, clinical outcomes were non-inferior to those of direct eculizumab recipients and the magnitude of MG-ADL improvement was comparable to that of the overall treatment group. The mean daily corticosteroid dose decreased from 21.21 ± 13.68 mg at baseline to 13.32 ± 10.42 mg at final follow-up (p < 0.0001) Adverse events were rare, with no treatment-related serious events. Eculizumab provides rapid and sustained clinical improvement in patients with MG, with a favorable safety profile. Patients with TAMG show a faster initial response. For patients with an inadequate response to FcRn inhibitors, eculizumab remains an effective rescue strategy.
- Open Access
- 3 June 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1781372
A predictive model for low-dose rituximab response in anti-acetylcholine receptor antibody-positive myasthenia gravis: establishment and validation
Background: Rituximab (RTX) represents an established therapeutic option for myasthenia gravis refractory to conventional immunotherapy. However, its heterogeneous efficacy across populations creates a challenge in clinical application, necessitating the development of robust predictive models to better identify patients likely to derive meaningful benefit from this treatment. Methods: This study retrospectively reviewed the patients who visited the research center and received RTX treatment between August 2019 and January 2025. The primary outcome measure was minimal symptom expression (MSE). A predictive model was constructed using logistic regression and presented in a nomogram. The performance of the model was evaluated by calculating the area under the receiver operating characteristic curve (AUC), with internal validation performed via the bootstrap method. The study population was divided into high- and low- probability groups according to Youden index. Calibration curves with 1000 replications bootstrap resampling were plotted to visualize the calibration of the nomogram. Decision curve analyzes (DCA) with 1000 replications bootstrap resampling were per formed to evaluate the clinical usefulness of the model. Results: A total of 117 patients were included. Five variables were screened including new-onset MG, baseline MG-ADL score, high CD19 + /CD27 + B lymphocyte proportion, high-dose prednisone, and early immunotherapy initiation. The model exhibited moderate discriminative ability with AUC value 0.777. Using a threshold probability of 0.534 derived from the Youden index, patients were stratified into high- and low-probability groups (sensitivity 72.7%, specificity 71.0%). The high-probability group showed a 6.52-fold higher likelihood of achieving MSE. The calibration plot showed that when the probability was between 0 and 0.7, the deviation calibration curve of the model was consistent with the ideal curve. Conclusion: This nomogram helps identify AChR-MG patients likely to attain MSE 6 months after low-dose rituximab, thereby supporting personalized therapeutic decision-making.
- 3 June 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1781372
Open AccessA predictive model for low-dose rituximab response in anti-acetylcholine receptor antibody-positive myasthenia gravis: establishment and validation
Background: Rituximab (RTX) represents an established therapeutic option for myasthenia gravis refractory to conventional immunotherapy. However, its heterogeneous efficacy across populations creates a challenge in clinical application, necessitating the development of robust predictive models to better identify patients likely to derive meaningful benefit from this treatment. Methods: This study retrospectively reviewed the patients who visited the research center and received RTX treatment between August 2019 and January 2025. The primary outcome measure was minimal symptom expression (MSE). A predictive model was constructed using logistic regression and presented in a nomogram. The performance of the model was evaluated by calculating the area under the receiver operating characteristic curve (AUC), with internal validation performed via the bootstrap method. The study population was divided into high- and low- probability groups according to Youden index. Calibration curves with 1000 replications bootstrap resampling were plotted to visualize the calibration of the nomogram. Decision curve analyzes (DCA) with 1000 replications bootstrap resampling were per formed to evaluate the clinical usefulness of the model. Results: A total of 117 patients were included. Five variables were screened including new-onset MG, baseline MG-ADL score, high CD19 + /CD27 + B lymphocyte proportion, high-dose prednisone, and early immunotherapy initiation. The model exhibited moderate discriminative ability with AUC value 0.777. Using a threshold probability of 0.534 derived from the Youden index, patients were stratified into high- and low-probability groups (sensitivity 72.7%, specificity 71.0%). The high-probability group showed a 6.52-fold higher likelihood of achieving MSE. The calibration plot showed that when the probability was between 0 and 0.7, the deviation calibration curve of the model was consistent with the ideal curve. Conclusion: This nomogram helps identify AChR-MG patients likely to attain MSE 6 months after low-dose rituximab, thereby supporting personalized therapeutic decision-making.